Senior Lecturer, University of Technology Sydney, Biomedical Engineering
Assoc Prof. Daniel Carter’s genetic barcoding proposal was one of two major 2023 research projects awarded $175,000 in funding by Neuroblastoma Australia.
A major problem hindering successful therapy in neuroblastoma is that cancer cells of a given tumour have differing genetic profiles, and therefore differing sensitivity to chemotherapy. Treatments fail in neuroblastoma because minor cancer cell populations are naturally drug resistant due to their unique genetic makeup, and these cells ultimately regrow as a highly drug-resistant ‘relapsed’ tumour.
To identify key genetic features that allow resistance to chemotherapy, Assoc. Prof. Carter will use novel genetic barcoding technology, that allows him and his team to track individual tumour cells when they are exposed to anti-cancer drugs in the lab.
Our plan is to ultimately apply these findings as a novel single-cell diagnostic method that allows for better prediction of patient response to chemotherapy and optimised drug treatment approaches individualised for each patient. Assoc. Prof. Daniel Carter
Enable this content?
This content is served by a third party, www.youtube.com. If enabled, www.youtube.com may collect information about your activity. Manage preferences to always allow this content.PreferencesEnable
IMPACT:
Thanks to the funds awarded by Neuroblastoma Australia, Assoc. Professor Carter has secured a major grant from NHRMC to develop this promising research further.
